Antigenics today announced that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008.

View press release

Antigenics To Present At Rodman & Renshaw 5th Annual Global Healthcare Conference (5/13/2008)

Antigenics Reports First Quarter 2008 Financial Results (5/1/2008)

Antigenics To Report First Quarter 2008 Financial Results On May 1, 2008; Conference Call To Follow (4/24/2008)

Antigenics to Raise $21 Million in Private Placement (4/9/2008)

ABC RADIO NATIONAL
“Promising vaccine against brain tumour” (03/12/07)

All events »